5-iodowillardiine selectively binds to a receptor for this compound. Lilly’s failed drug pomeglutemad targeted this compound’s receptors in an attempt to treat schizophrenia, as the hypofunction of this compound’s receptors is a hypothesis behind the cause of schizophrenia. Olney’s lesions were historically believed to caused by inhibitors of receptors of this compound, whose activity is increased in response to BDNF. Some cases of Rasmussen’s encephalitis see autoantibodies target this compound’s receptors. EAATs transport this compound, whose GPCRs are strongly antagonized by quisqualate. Memantine and ketamine block a receptor for this compound; that receptor may also be blocked by magnesium ions. Ionotrophic receptors for this compound may react to kainate, AMPA, and NMDA and are involved in long-term potentiation and synaptic plasticity. GABA is synthesized by decarboxyling this compound. For 10 points, name this excitatory neurotransmitter which like aspartate is an amino acid with an acidic side chain.
5-iodowillardiine selectively binds to a receptor for this compound. Lilly’s failed drug pomeglutemad targeted this compound’s receptors in an attempt to treat schizophrenia, as the hypofunction of this compound’s receptors is a hypothesis behind the cause of schizophrenia. Olney’s lesions were historically believed to caused by inhibitors of receptors of this compound, whose activity is increased in response to BDNF. Some cases of Rasmussen’s encephalitis see autoantibodies target this compound’s receptors. EAATs transport this compound, whose GPCRs are strongly antagonized by quisqualate. Memantine and ketamine block a receptor for this compound; that receptor may also be blocked by magnesium ions. Ionotrophic receptors for this compound may react to kainate, AMPA, and NMDA and are involved in long-term potentiation and synaptic plasticity. GABA is synthesized by decarboxyling this compound. For 10 points, name this excitatory neurotransmitter which like aspartate is an amino acid with an acidic side chain.
5-iodowillardiine selectively binds to a receptor for this compound.